Celera Narrowing Down Proteins in Prognostic Panel for Non-Small Cell Lung Cancer Detection | GenomeWeb

By Turna Ray

Celera has validated
its mass-spectrometry-based approach for identifying circulating protein biomarkers that detect non-small cell lung cancer at all stages and is currently in the process of deciding whether to commercialize a prognostic assay based on a six- or a nine-protein marker panel.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.